GROWTHFORGE · BEACON + ORBIT

Cheap-to-Truth Radar.

Fresh public signals that may deserve a closer drug-development look. GrowthForge scans structured trial records daily and publishes source-backed facts plus a transparent priority-to-inspect heuristic.

Radar priority is not a probability of success, investment rating, safety conclusion, or recommendation. It means only: “this public record contains features that make it worth inspecting sooner.”

LATEST RADAR

Signals to inspect, not conclusions to believe.

Source: ClinicalTrials.gov structured records. Each item links back to the originating registry entry.

NCT06984328TERMINATEDUpdated 2026-09-30

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Acasunlimab, Pembrolizumab · Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

Radar priority82/100

Priority means “inspect sooner,” not “good asset.”